Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Galapagos   /   Galapagos 200 euro per aandeel

Aandeel Galapagos AEX:GLPG.NL, BE0003818359

Laatste koers (eur) Verschil Volume
25,700   +0,200   (+0,78%) Dagrange 25,320 - 25,800 86.098   Gem. (3M) 87,9K

Galapagos 200 euro per aandeel

Volgen
957 Posts
Pagina: «« 1 ... 17 18 19 20 21 ... 48 »» | Laatste | Omlaag ↓
  1. [verwijderd] 18 april 2018 23:05
    quote:

    inspirator schreef op 18 april 2018 22:53:

    FDA panel geeft as maandag scores weer van Filgotinib vwb Arthritis.

    Met 99% zekerheid dat koers Galapagos volgende week boven 100 euro staat.

    Gilead Sciences Inc. and Galapagos NV may also reflect read-through to their experimental filgotinib treatment, with upside for Galapagos shares of 5 percent and downside risk of 10 percent, Credit Suisse estimates.

    www.bloomberg.com/news/articles/2018-...
    dus 5% up als er wat goed nieuws is en mocht het tegenvallen dan een down van 10% vind ik toch niet zo leuk om te lezen dus wachten maar af op .........
  5. [verwijderd] 19 april 2018 20:45
    Krijgt Onno nog gelijk.

    It is just the beginning.

    FDA staff raises safety concerns over Lilly/Incyte arthritis drug

    This could be a positive for competitors such as AbbVie and Gilead and Galapagos that have their own oral JAK inhibitors in late-stage development," wrote Credit Suisse analysts.

    kfgo.com/news/articles/2018/apr/19/fd...
  8. [verwijderd] 20 april 2018 01:21
    quote:

    inspirator schreef op 19 april 2018 20:45:

    Krijgt Onno nog gelijk.

    It is just the beginning.

    FDA staff raises safety concerns over Lilly/Incyte arthritis drug

    This could be a positive for competitors such as AbbVie and Gilead and Galapagos that have their own oral JAK inhibitors in late-stage development," wrote Credit Suisse analysts.

    kfgo.com/news/articles/2018/apr/19/fd...
    Concurrentie van Galapagos krijgt klap en met laatste persbericht wordt bevestigd dat produkten van Galapagos blockbusters zijn.
    Hiedoor is kans op overnamebid op korte termijn erg groot.

    Koers Galapagos gaat morgen naar all time high en klimt dan richting 200 euro.

    Galapagos creates new warrant plan

    19 April 2018 at 22:01 CET

    Mechelen, Belgium; 19 April 2018, 22.01 CET; regulated information -- Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its board of directors created 1,585,000 warrants under new warrant plans for the benefit of employees, future employees, directors and a consultant of the company and its subsidiaries.

    On 19 April 2018, the board of directors of Galapagos approved the "Warrant Plan 2018", a warrant plan intended mainly for certain (future) employees of the company and its subsidiaries, and also for directors and an independent consultant of the company, and the "Warrant Plan 2018 RMV," a warrant plan intended for certain employees of its French subsidiary, Galapagos SASU, within the framework of the authorized capital. Under these warrant plans, 1,585,000 warrants were created, subject to acceptances, and offered to the beneficiaries of the plans.

    The offer of warrants to directors remains subject to approval of the annual shareholders' meeting to be held on 24 April 2018.

    The warrants have an exercise term of eight years as of the date of the offer and have an exercise price of €79.88 (the average closing price of the share on Euronext Amsterdam and Brussels during the thirty days preceding the date of the offer). The warrants are not transferable and can in principle not be exercised prior to 1 January 2022. Each warrant gives the right to subscribe to one new Galapagos share. Should the warrants be exercised, Galapagos will apply for the listing of the resulting new shares on a regulated stock market. The warrants as such will not be listed on any stock market.

    Galapagos' total share capital currently amounts to €277,122,928.92; the total number of securities conferring voting rights is 51,234,962, which is also the total number of voting rights (the "denominator"), and all securities conferring voting rights and all voting rights are of the same category. The total number of rights (warrants) to subscribe to not yet issued securities conferring voting rights is 3,660,623, which equals the total number of voting rights that may result from the exercise of these warrants, and excludes the 1,585,000 warrants of Warrant Plan 2018 and Warrant Plan 2018 RMV, which were created subject to acceptance. Galapagos does not have any convertible bonds or shares without voting rights outstanding.
  9. [verwijderd] 20 april 2018 08:53
    quote:

    inspirator schreef op 19 april 2018 20:45:

    Krijgt Onno nog gelijk.

    It is just the beginning.

    FDA staff raises safety concerns over Lilly/Incyte arthritis drug

    This could be a positive for competitors such as AbbVie and Gilead and Galapagos that have their own oral JAK inhibitors in late-stage development," wrote Credit Suisse analysts.

    kfgo.com/news/articles/2018/apr/19/fd...
    Concurrent van Filgotinb vwb Arthritis is knockout.
    Dit gaat koers van Galapagos weer naar 100 euro leiden,
  12. [verwijderd] 23 april 2018 18:56
    20 programs to enter clinic or preclinical development.
    Gilead knows that some molecules could make a future shift in IBD-treatment, or could lead to dual cominations with Filgotinib.
    Filgotinib in 10 indications (RA, Crohn, UC, PsA, AS, Lupus, Uveitis, JIA, Sjogren and CGvHD).
    Gilead in-licensed this molecule, but will have to pay $1.2 billion development/regulatory... milestones and 20-30% royalties to Galapagos by further success (Big 5 EU and Benelux profit split!).
    Galapagos is very interesting for Gilead.
    The pipeline is expanding rapidly and they have multiple Disease Modifying Targets which has proven itself in patients.
    If there will be a takeover..?
    The Board of Galapagos doesn't want a takeover. They have ambitions for themselves.
    They also seek a strategic partnership with Big Pharma, so Gilead is faced with another strategic stakeholder.
    Maybe Gilead will respect this independancy of Galapagos in favor of first right negotiations or other privileges...
  15. [verwijderd] 25 april 2018 08:29
    quote:

    inspirator schreef op 24 april 2018 23:15:

    Notulen van AVA 24-4-2018

    www.glpg.com/docs/view/5adf4bc426082-nl
    Op de AVA waren gisteren 26,7 miljoen aandelen Galapagos vertegenwoordigd.

    De grote jongens
    Citi 7,3 miljoen
    Gilead 7,3 miljoen
    BNP 6,1 miljoen
    Deutsche Bank 3,9 miljoen

    Verleenden alle volmacht voor goedkeuring van voorstellen aan Galapagos.

    Deze jongens weten meer en regisseren overname van Galapagos.

    Vergoeding voor bestuur is lucratief warrantplan.

    Jammer dat Onno vd Stolpe instemt met een schamel overnamebod op aandelen Galapagos.

  16. [verwijderd] 25 april 2018 17:54
    quote:

    inspirator schreef op 25 april 2018 08:29:

    [...]

    Op de AVA waren gisteren 26,7 miljoen aandelen Galapagos vertegenwoordigd.

    De grote jongens
    Citi 7,3 miljoen
    Gilead 7,3 miljoen
    BNP 6,1 miljoen
    Deutsche Bank 3,9 miljoen

    Verleenden alle volmacht voor goedkeuring van voorstellen aan Galapagos.

    Deze jongens weten meer en regisseren overname van Galapagos.

    Vergoeding voor bestuur is lucratief warrantplan.

    Jammer dat Onno vd Stolpe instemt met een schamel overnamebod op aandelen Galapagos.

    Opgeruimd staat netjes.
    Laat dit net de banken zijn die vandaag de stoplossen hebben getriggerd op de turbo’s en boosters.
    Anders gaat het de banken geld kosten als overnamebod morgen komt.
    Banken zijn alleen van het incasseren.
  17. [verwijderd] 25 april 2018 22:24
    Galapagos is delivering on a very productive biotech pipeline. The first quarter of 2018 brought us closer to the expected start in the second quarter of the next patient studies in our osteoarthritis, atopic dermatitis, and cystic fibrosis programs.

    Dat is mooi, want we zitten immers inmiddels in kwartaal 2.

    Dus nog binnen 65 dagen meer Galapagos nieuws.

  18. [verwijderd] 25 april 2018 22:45
    quote:

    inspirator schreef op 25 april 2018 22:24:

    Galapagos is delivering on a very productive biotech pipeline. The first quarter of 2018 brought us closer to the expected start in the second quarter of the next patient studies in our osteoarthritis, atopic dermatitis, and cystic fibrosis programs.

    Dat is mooi, want we zitten immers inmiddels in kwartaal 2.

    Dus nog binnen 65 dagen meer Galapagos nieuws.

    Letter from the management

    Dear shareholders,

    We reported another quarter of solid pipeline progress in the first quarter of 2018, as we prepared for the next wave of late stage studies, finished up execution on several other patient studies, and moved our early pipeline forward.

    In our osteoarthritis, atopic dermatitis, and cystic fibrosis programs, we are preparing for the next patient studies in the second quarter. Importantly, we received feedback from regulatory authorities for our ISABELA global pivotal studies with GLPG1690 in idiopathic pulmonary fibrosis, expected to start in the second half of 2018. We await the next round of filgotinib clinical study results, starting with the EQUATOR studies in psoriatic arthritis in the second quarter.

    Onno van de Stolpe, CEO of Galapagos (photo)
    The coming year will be data-rich, as we expect the first Phase 3 data with filgotinib in rheumatoid arthritis, along with an interim decision to move to Phase 3 in the ulcerative colitis trial and readouts in our trials in ankylosing spondylitis and psoriatic arthritis. In cystic fibrosis, we will see topline results from the PELICAN trial and a first interim readout with FALCON, a patient study of our first triple combination therapy. We expect to launch pivotal trials with GLPG1690 in IPF, building our fully proprietary IPF franchise. And with our planned start of Phase 2 studies for GLPG1205, GLPG1972, MOR106, and a second CF triple combination, we set the foundations for the next set of clinical results. Meanwhile, we continue to expand our organization to be able to execute the increasing number of clinical studies and to be ready for the anticipated market introduction of our drug candidates.

    Galapagos ended the first quarter of 2018 with a strong balance sheet. We are continuing to grow our late stage development organization to execute on our successful programs. The Galapagos share of proprietary late stage development is growing, leading to increased costs for our company. During 2018 we expect to be running 13 Phase 2 studies. All this will contribute to our financial guidance for operational cash burn between €220 and €240 million for full year 2018.
  19. [verwijderd] 26 april 2018 19:01
    quote:

    inspirator schreef op 25 april 2018 22:24:

    Galapagos is delivering on a very productive biotech pipeline. The first quarter of 2018 brought us closer to the expected start in the second quarter of the next patient studies in our osteoarthritis, atopic dermatitis, and cystic fibrosis programs.

    Dat is mooi, want we zitten immers inmiddels in kwartaal 2.

    Dus nog binnen 65 dagen meer Galapagos nieuws.

    Deze keer gaat Onno zijn belofte niet breken.
    Nog maximaal 64 dagen te gaan voor goede nieuws.
957 Posts
Pagina: «« 1 ... 17 18 19 20 21 ... 48 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium

Galapagos meldt fraai succes rond nieuwe therapie: zit er weer muziek in het aandeel?

Het laatste advies leest u als abonnee van IEX Premium

Inloggen Word Abonnee

Galapagos Nieuws

  1. Galapagos: bemoedigende nieuwe resultaten met recidief/refractair non-Hodgkin lymfoom
  2. Kepler Cheuvreux zet Galapagos op verkooplijst
  3. Klinische resultaten Galapagos steunen celtherapie-hypothese
  4. Deutsche Bank verlaagt koersdoel Galapagos
  5. Financials en Shell doen goede zaken op terughoudend Damrak
  6. Galapagos herhaalt cash burn voor 2024
  7. Galapagos benoemt investeerder Nodelman in bestuur
  8. EcoR1 nog groter in Galapagos
  9. EcoR1 groter in Galapagos
  10. FMR LLC kleiner in Galapagos